Scarica l'app Stockscreener
238.97
1.35%
-3.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$242.23
Aprire:
$241.54
Volume 24 ore:
2.52M
Relative Volume:
2.23
Capitalizzazione di mercato:
$33.61B
Reddito:
$5.54B
Utile/perdita netta:
$1.52B
Rapporto P/E:
23.04
EPS:
10.3734
Flusso di cassa netto:
$1.74B
1 W Prestazione:
+3.88%
1M Prestazione:
+4.70%
6M Prestazione:
+6.34%
1 anno Prestazione:
-11.49%
Intervallo 1D:
$237.87
$242.57
Intervallo di 1 settimana:
$230.08
$242.63
Portata 52W:
$180.26
$277.67
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
238.97 | 33.61B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
426.70 | 150.74B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
191.75 | 52.23B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.18 | 31.99B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.96 | 31.55B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-08-19 | Iniziato | Rothschild & Co Redburn | Neutral |
| 2026-07-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-07-13 | Downgrade | Citigroup | Buy → Neutral |
| 2026-06-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-04-15 | Iniziato | JP Morgan | Overweight |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Mizuho Adjusts Price Target on ResMed to $240 From $235 - www.marketscreener.com
EBITDA of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed Q4 2026 Earnings Call Transcript - Benzinga
Is ResMed Facing Fresh Questions Before Results (ASX:RMD)? - Kalkine Media
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com South Africa
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com Nigeria
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Form 4 ResMed Inc For: 8 October By Investing.com - Investing.com Nigeria
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance Singapore
ResMed (NYSE:RMD) Stock: Insider Michael Farrell Sells 4,991 Shares - MarketBeat
ResMed chairman & CEO Michael Farrell sells $1.1m in shares - Investing.com
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
What Is Shaping Breville, Treasury Wine and ResMed? - Kalkine Media
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Michael Farrell proposes selling 4,991 ResMed (NYSE: RMD) shares through Fidelity. - Stock Titan
ResMed (NYSE:RMD) Offers Dividend Investors a Sustainable Payout Built on Quality Fundamentals - ChartMill
ResMed plans USD 1.5 billion share repurchase and RBC raises target for ResMed stock - ad-hoc-news.de
Resmed (ASX:RMD) Shares Slide Over the Year Even as Record Q4 Revenue and a Higher Dividend Close Fiscal 2026 - Kalkine
ResMed stock pre-market at EUR 199.20: plus 0.48 percent - ad-hoc-news.de
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
ResMed Inc Reports CDI and Common Stock Movements for September 2026 - Kalkine
RSMDF | RESMED INC ORD Insider Trading - Quiver Quantitative
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Stifel reiterates Hold on ResMed stock amid market share concerns - Investing.com
ResMed Inc. $RMD Shares Sold by Envestnet Asset Management Inc. - MarketBeat
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
RESMED INC ($RMD) CEO 2026 Pay Revealed - Quiver Quantitative
RESMED INC ($RMD) CEO 2026 Pay Revealed - Quiver Quantitative
RESMED INC SEC Filing (Oct 1, 2026) - Stock Titan
Form 4 ResMed Inc For: 1 October By Investing.com - Investing.com Nigeria
A 10% dividend increase is part of ResMed (RMD)'s FY2027 stockholder return plan. - Stock Titan
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026 - Moomoo
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
Form ARS RESMED INC For: Jun 30 - StreetInsider
Will ResMed (ASX:RMD) stay a fund manager favourite? - Kalkine Media
Price to cash flow ratio of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed stock trades at EUR 195.18 after RBC raises target - AD HOC NEWS
Can ResMed (ASX:RMD) Hit Its Outlook After Retiring the Astral Ventilator? - Kalkine Media
Net debt of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed Inc. (NYSE:RMD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
ResMed stock trades at USD 221.89 after RBC target hike - AD HOC NEWS
ResMed stock heads into the open after September 24 data - AD HOC NEWS
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance Singapore
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed stock reports 10 percent fiscal revenue growth - AD HOC NEWS
ResMed Inc. $RMD Shares Purchased by State Street Corp - MarketBeat
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Resmed Inc Azioni (RMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO |
Oct 07 '26 |
Sale |
226.33 |
4,991 |
1,129,637 |
479,803 |
| Farrell Michael J. | Officer |
Oct 07 '26 |
Proposed Sale |
226.33 |
4,991 |
1,129,638 |
0 |
| Farrell Michael J. | Officer |
Sep 08 '26 |
Proposed Sale |
226.22 |
4,991 |
1,129,064 |
0 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Sale |
222.44 |
4,991 |
1,110,191 |
466,256 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
| FARRELL PETER C | Director |
Sep 02 '26 |
Sale |
234.73 |
970 |
227,688 |
51,803 |
| Peter C Farrell | Director |
Sep 02 '26 |
Proposed Sale |
234.65 |
970 |
227,608 |
0 |
| Farrell Michael J. | Chairman and CEO |
Aug 07 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
| Farrell Michael J. | Chairman and CEO |
Aug 07 '26 |
Sale |
205.69 |
4,991 |
1,026,596 |
466,256 |
| Farrell Michael J. | Officer |
Aug 07 '26 |
Proposed Sale |
205.69 |
4,991 |
1,026,596 |
0 |
0.60%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):